Monitoring the response of breast tumors to neoadjuvant chemotherapy using multimodal magnetic resonance and optical imaging – a case study
Bin Deng1,2,3, Ailis Muldoon1,2, Pedro Itriago4, Wei-Ching Lo5, Mansi Saksena2,3, Samuel Patz3,6, Ralph Sinkus7, Steven J. Isakoff3,8, and Stefan A. Carp1,2,3
1Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, 2Department of Radiology, Massachusetts General Hospital, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4Siemens Medical Solutions, Houston, TX, United States, 5Siemens Medical Solutions, Boston, MA, United States, 6Department of Radiology, Brigham and Women’s Hospital, Boston, MA, United States, 7Laboratory for Vascular Translational Science (LVTS), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France, 8Cancer Center, Massachusetts General Hospital, Boston, MA, United States
Functional imaging is advantageous in monitoring neoadjuvant chemotherapy (NACT) since changes in tumor physiology manifest earlier than actual tumor shrinkage. We leveraged a custom breast coil for multimodal T1, DWI, MRE, and near-infrared optical imaging to evaluate the response of breast tumors to NACT. In this case study of a patient who achieved pathologic complete response, concordant changes in tumor size, ADC, stiffness and total hemoglobin concentration have been observed. This multiparametric approach could help us gain a comprehensive understanding of the multitude of simultaneous physiological changes in tumors related to microenvironment, angiogenesis, and metabolism as a result of NACT.
This abstract and the presentation materials are available to members only;
a login is required.